Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Nasdaq"

18 News Found

Merck completes acquisition of Prometheus Biosciences
News | June 17, 2023

Merck completes acquisition of Prometheus Biosciences

Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions


Sun Pharma completes acquisition of Concert Pharmaceuticals
News | March 07, 2023

Sun Pharma completes acquisition of Concert Pharmaceuticals

The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market


Merck completes tender offer to acquire Imago BioSciences
News | January 12, 2023

Merck completes tender offer to acquire Imago BioSciences

Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago


CNS Pharmaceuticals appoints Faith L. Charles as Chair of the Board of Directors
People | January 04, 2023

CNS Pharmaceuticals appoints Faith L. Charles as Chair of the Board of Directors

Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations


PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
Biotech | August 16, 2022

PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital

Company appoints five new independent directors to reconstituted board


Iktos and Zealand Pharma to develop AI technology for peptide drug design
Digitisation | June 22, 2022

Iktos and Zealand Pharma to develop AI technology for peptide drug design

Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design


AIkido Pharma appoints Soo Yu as Director
People | June 11, 2022

AIkido Pharma appoints Soo Yu as Director

New Director supports NASDAQ rule on diversity


Innate Pharma announces IPH5201 phase 2 study in lung cancer
News | June 04, 2022

Innate Pharma announces IPH5201 phase 2 study in lung cancer

Innate to receive $5M milestone payment from AstraZeneca